非布司他用于晚期慢性肾脏病高尿酸血症患者 - Suppr

Suppr

超能文献

Febuxostat in Hyperuricemic Patients With Advanced CKD.

作者信息

Lim Doo-Ho, Oh Ji Seon, Ahn Soo Min, Hong Seokchan, Kim Yong-Gil, Lee Chang-Keun, Choi Seung Won, Yoo Bin

机构信息

Asan Medical Center, Seoul, Republic of Korea.

Ulsan University Hospital, Ulsan, Republic of Korea.

出版信息

Am J Kidney Dis. 2016 Nov;68(5):819-821. doi: 10.1053/j.ajkd.2016.07.001. Epub 2016 Aug 5.

DOI:10.1053/j.ajkd.2016.07.001

PMID:27503183

Abstract

摘要

相似文献

Febuxostat in Hyperuricemic Patients With Advanced CKD.非布司他用于晚期慢性肾脏病高尿酸血症患者

Am J Kidney Dis. 2016 Nov;68(5):819-821. doi: 10.1053/j.ajkd.2016.07.001. Epub 2016 Aug 5.

Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease .非布司他在别嘌醇难治性高尿酸血症慢性肾脏病患者中的疗效

Int J Clin Pharmacol Ther. 2018 Jul;56(7):321-327. doi: 10.5414/CP202735.

Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.比较别嘌醇和非布司他在高尿酸血症慢性肾脏病患者中的护肾作用。

Int Urol Nephrol. 2019 Mar;51(3):467-473. doi: 10.1007/s11255-018-2051-2. Epub 2019 Jan 2.

Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.非布司他在轻至中度慢性肾脏病高尿酸血症患者中的疗效：一项随机临床试验的荟萃分析：一篇遵循PRISMA标准的文章

Medicine (Baltimore). 2018 Mar;97(13):e0161. doi: 10.1097/MD.0000000000010161.

Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.将黄嘌呤氧化还原酶抑制剂从非布司他转换为托匹司他对尿蛋白排泄的影响。

Clin Exp Nephrol. 2017 Apr;21(2):356-357. doi: 10.1007/s10157-017-1388-7. Epub 2017 Feb 28.

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).非布司他与托匹司他治疗合并心血管疾病的高尿酸血症的转换试验：慢性肾脏病亚组分析（TROFEO CKD试验）

Ann Thorac Cardiovasc Surg. 2020 Aug 20;26(4):202-208. doi: 10.5761/atcs.oa.19-00162. Epub 2019 Nov 21.

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).非布司他与别嘌醇治疗慢性肾脏病心脏手术患者高尿酸血症的比较（CKD的NU-FLASH试验）

J Cardiol. 2015 Oct;66(4):298-303. doi: 10.1016/j.jjcc.2014.12.017. Epub 2015 Jan 31.

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.非布司他在慢性肾脏病伴无症状高尿酸血症患者中降低肾小球滤过率下降速度的疗效：一项 6 个月、双盲、随机、安慰剂对照试验。

Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30.

Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.非布司他在慢性肾脏病3A期至5D期的治疗疗效研究。

Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1050-1056. doi: 10.4103/1319-2442.243953.

Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.中重度慢性肾脏病的降尿酸治疗

Perm J. 2018;22:17-142. doi: 10.7812/TPP/17-142.

引用本文的文献

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.慢性肾脏病相关痛风管理：G-CAN 共识声明中关于研究重点的内容

Nat Rev Rheumatol. 2021 Oct;17(10):633-641. doi: 10.1038/s41584-021-00657-4. Epub 2021 Jul 30.

Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.肾脏损伤患者降尿酸治疗的疗效与安全性：一项由全球痛风与高尿酸血症网络（GCAN）发起的文献综述

Rheumatol Adv Pract. 2021 Jan 4;5(1):rkaa073. doi: 10.1093/rap/rkaa073. eCollection 2021.

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.黄嘌呤氧化酶抑制剂非布司他的副作用及相互作用

Pharmaceuticals (Basel). 2018 May 25;11(2):51. doi: 10.3390/ph11020051.

Management of Gout and Hyperuricemia in CKD.慢性肾脏病患者痛风和高尿酸血症的管理

Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验